Because Turan used propofol in induction in the general group and halothane in maintenance, both agents may be considered to have an effect on the outcomes.
Neratinib and trastuzumab exert their effect on the HER2 receptor at various molecular sites, and it has been suggested that the combination of both agents may be synergistic.
Nonetheless, it must be noted that in clinical practice both agents may be used in a sequence, an approach which has not been evaluated in the Greek model due to limitations concerning the data availability.
Nonetheless, it must be noted that in clinical practice both agents may be used together to increase the number of follicles, oocytes, embryos, and/or pregnancies in treated patients.
However, it must be noted that in clinical practice both agents may be used together to increase the number of follicles, oocytes, embryos, and/or pregnancies in treated patients, an approach which has not been evaluated in Greece or reported in the literature due to obvious limitations.
However, it must be noted that in clinical practice both agents may be used together to increase the number of follicles, oocytes, embryos, and/or pregnancies in treated patients, an approach that has not been evaluated locally or in the relevant literature, for obvious reasons.
These studies, in line with the present study, suggest that in mixed infections the burden of one or both the infectious agents may be increased, one or both may be suppressed or one may be increased and the other suppressed.
Combining NFV with BZ, both FDA-approved agents, may be a novel way to overcome BZ resistance in MM.
Finally, SiNPs that contain at least two different functional agents may be more powerful for both tumor imaging and therapy.
